
Pharmacally
Atopic Dermatitis
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Atopic Dermatitis
Health TidingsLynk Expands Simcere Deal for Zemprocitinib in Atopic DermatitisLynk Pharmaceuticals has expanded its commercialization partnership with Simcere to include zemprocitinib for moderate-to-severe atopic dermatitis in adults across Greater China.Fact-Checked
Clinical TrialsSitryx Reports Early Improvements in Atopic Dermatitis With SYX-5219Sitryx Therapeutics reports preliminary Phase 1b findings for SYX-5219, an investigational oral PKM2 modulator, with placebo-adjusted improvements in eczema severity and itch after six weeks.Fact-Checked
Clinical TrialsPfizer’s Tilrekimig Achieves EASI-75 Across Doses in Phase 2 Atopic Dermatitis StudyPfizer’s investigational trispecific antibody tilrekimig achieved the primary EASI-75 endpoint across all evaluated doses at Week 16 in a Phase 2 study of adults with moderate-to-severe atopic dermatitis.Fact-Checked
Clinical TrialsZumilokibart Phase 2 Results Show EASI-75 Benefit in Atopic DermatitisAbbVie reported positive Phase 2 APEX Part B results for investigational zumilokibart in moderate to severe atopic dermatitis, with all three dose regimens significantly improving EASI-75 versus placebo…Fact-Checked
Health TidingsAlmirall’s New Lebrikizumab and Tildrakizumab Data Highlight Long-Term Outcomes in Atopic Dermatitis and PsoriasisAlmirall is presenting new clinical and real-world evidence for lebrikizumab in atopic dermatitis and tildrakizumab in psoriasis at EADV 2026, including five-year ADlong and two-year POSITIVE findings.Fact-Checked
Clinical TrialsGalderma’s Nemluvio Shows Sustained Atopic Dermatitis Benefits in 3-Year ARCADIA DataGalderma reports three-year ARCADIA long-term extension data showing sustained improvements in skin lesions, itch, sleep disturbance and quality of life with Nemluvio in patients aged 12 years and…Fact-Checked
Clinical TrialsEvommune Discontinues EVO756 in Atopic Dermatitis After Earlier CSU SetbackEvommune’s oral MRGPRX2 antagonist EVO756 failed to meet efficacy endpoints in a Phase 2b trial of moderate-to-severe atopic dermatitis.Fact-Checked
Clinical TrialsRezpegaldesleukin Delivers Positive Phase 2b Results in Atopic Dermatitis, Supporting T-Reg ModulationNektar Therapeutics’ rezpegaldesleukin met the primary and key secondary endpoints in the Phase 2b REZOLVE-AD trial in moderate-to-severe atopic dermatitis, with the 24 μg/kg every-two-weeks regimen delivering a…Fact-Checked
Health TidingsEuropean Commission Approves Opzelura for Adults with Moderate Atopic Dermatitis After Inadequate Response to Standard Topical TherapiesThe European Commission has approved Opzelura (ruxolitinib) cream for adults with moderate atopic dermatitis who have an inadequate response or cannot use topical corticosteroids and calcineurin inhibitors.Fact-Checked
Clinical TrialsOrganon Reports Positive Phase 3 VTAMA Data in Atopic DermatitisOrganon presented the first age-stratified pooled Phase 3 ADORING trial analysis at SPD 2026, showing that VTAMA (tapinarof) cream achieved early and consistent improvements in skin clearance and…Fact-Checked
Clinical TrialsInnoCare’s Soficitinib Meets Phase III Endpoint in Atopic DermatitisInnoCare Pharma announced positive topline results from its registrational Phase III trial of soficitinib (ICP-332) in moderate-to-severe atopic dermatitis.Fact-Checked
Clinical TrialsLEO Pharma Reports Positive Phase II TRAPEDS-1 Data Supporting Long-Term Safety of Tralokinumab in Children with Atopic DermatitisLEO Pharma announced positive topline results from the Phase II TRAPEDS-1 trial of tralokinumab in children aged 6–11 years with moderate-to-severe atopic dermatitis.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.